MX2018014443A - 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas. - Google Patents
3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas.Info
- Publication number
- MX2018014443A MX2018014443A MX2018014443A MX2018014443A MX2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- dihydropyridazine
- diphenyl
- oxo
- preparing
- Prior art date
Links
- MOVDLRJXICFWKP-UHFFFAOYSA-N 3-oxo-2,6-diphenylpyridazine-4-carboxamide Chemical class O=C1N(N=C(C=C1C(=O)N)C1=CC=CC=C1)C1=CC=CC=C1 MOVDLRJXICFWKP-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención cubre compuestos de 3-oxo-2,6-difenil-2,3-di hidropiridazin-4-carboxamida de fórmula general (I): (ver Fórmula) en la cual R1, R2, R3, R4, R5 y R6 son según lo definido en la presente invención, métodos para preparar dichos compuestos, compuestos intermedios útiles para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y la utilización de dichos compuestos para manufacturar composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular del cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización aberrante del AHR, como un agente único o en combinación con otros ingredientes activos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016083308 | 2016-05-25 | ||
| CN2017074408 | 2017-02-22 | ||
| PCT/EP2017/062355 WO2017202816A1 (en) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014443A true MX2018014443A (es) | 2019-04-15 |
Family
ID=58745251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014443A MX2018014443A (es) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11040035B2 (es) |
| EP (1) | EP3464248B1 (es) |
| JP (1) | JP6964096B2 (es) |
| KR (1) | KR20190009369A (es) |
| CN (1) | CN109863140B (es) |
| AU (1) | AU2017269870A1 (es) |
| BR (1) | BR112018074185A2 (es) |
| CA (1) | CA3025227A1 (es) |
| CL (1) | CL2018003345A1 (es) |
| CO (1) | CO2018012654A2 (es) |
| CR (1) | CR20180556A (es) |
| CU (1) | CU20180143A7 (es) |
| DO (1) | DOP2018000256A (es) |
| EA (1) | EA201892666A1 (es) |
| EC (1) | ECSP18087725A (es) |
| IL (1) | IL263046A (es) |
| MA (1) | MA45087A (es) |
| MX (1) | MX2018014443A (es) |
| NI (1) | NI201800124A (es) |
| PE (1) | PE20190509A1 (es) |
| PH (1) | PH12018502472A1 (es) |
| SG (1) | SG11201810366WA (es) |
| SV (1) | SV2018005787A (es) |
| TN (1) | TN2018000392A1 (es) |
| TW (1) | TW201742859A (es) |
| UY (1) | UY37256A (es) |
| WO (1) | WO2017202816A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
| JOP20190193A1 (ar) * | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
| US11591311B2 (en) | 2017-11-21 | 2023-02-28 | Bayer Aktiengesellschaft | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
| PT3580211T (pt) * | 2017-11-21 | 2021-02-01 | Deutsches Krebsforsch | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro |
| WO2019101647A1 (en) * | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
| WO2019101642A1 (en) * | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
| SG11202101441SA (en) | 2018-08-24 | 2021-03-30 | Jaguahr Therapeutics Pte Ltd | Tetrahydropyridopyrimidine derivatives as ahr modulators |
| US20210395242A1 (en) | 2018-08-31 | 2021-12-23 | Jaguahr Therapeutics Pte Ltd | Heterocyclic compounds as ahr modulators |
| CN109771437B (zh) * | 2019-03-28 | 2023-03-17 | 西安交通大学医学院第一附属医院 | 三氟胸苷在制备治疗三阴性乳腺癌药物中的应用 |
| EP3715471A1 (en) * | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
| US20220289679A1 (en) * | 2019-07-29 | 2022-09-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
| WO2021122434A1 (en) * | 2019-12-16 | 2021-06-24 | Bayer Aktiengesellschaft | Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer |
| CA3167283A1 (en) | 2020-01-10 | 2021-07-15 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| AU2021226411A1 (en) | 2020-02-26 | 2022-09-22 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of AhR signalling |
| JP7651590B2 (ja) * | 2020-03-27 | 2025-03-26 | ドン－ア エスティ カンパニー リミテッド | アミノピリミジン誘導体およびアリール炭化水素受容体モジュレーターとしてのその使用 |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| CN114685426A (zh) * | 2020-12-28 | 2022-07-01 | 苏州泽璟生物制药股份有限公司 | 磺酰胺类抑制剂及其制备方法和应用 |
| WO2023043753A1 (en) * | 2021-09-14 | 2023-03-23 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| AU756275B2 (en) * | 1998-08-14 | 2003-01-09 | Nihon Nohyaku Co., Ltd. | Pyridazinone derivatives |
| IL154709A0 (en) | 2000-09-18 | 2003-10-31 | Eisai Co Ltd | Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same |
| FR2847253B1 (fr) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| FR2847235B1 (fr) | 2002-11-20 | 2005-07-08 | Essilor Int | Emballage de protection et de calage pour objets a contour circulaire |
| AR057986A1 (es) * | 2005-11-21 | 2008-01-09 | Japan Tobacco Inc | Compuesto heterociclico y su uso farmaceutico |
| WO2009142732A2 (en) | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| CN107648216B (zh) | 2010-07-27 | 2021-03-30 | 波士顿大学管理委员会 | 作为新型癌症疗法的芳烃受体(AhR)调节剂 |
| US20170173008A1 (en) | 2014-03-19 | 2017-06-22 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
| JOP20190193A1 (ar) * | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
-
2017
- 2017-05-23 MA MA045087A patent/MA45087A/fr unknown
- 2017-05-23 TN TNP/2018/000392A patent/TN2018000392A1/en unknown
- 2017-05-23 WO PCT/EP2017/062355 patent/WO2017202816A1/en not_active Ceased
- 2017-05-23 CU CU2018000143A patent/CU20180143A7/es unknown
- 2017-05-23 JP JP2018561224A patent/JP6964096B2/ja active Active
- 2017-05-23 CN CN201780046149.5A patent/CN109863140B/zh active Active
- 2017-05-23 PE PE2018003109A patent/PE20190509A1/es unknown
- 2017-05-23 AU AU2017269870A patent/AU2017269870A1/en not_active Abandoned
- 2017-05-23 MX MX2018014443A patent/MX2018014443A/es unknown
- 2017-05-23 US US16/303,539 patent/US11040035B2/en active Active
- 2017-05-23 CR CR20180556A patent/CR20180556A/es unknown
- 2017-05-23 KR KR1020187037050A patent/KR20190009369A/ko not_active Ceased
- 2017-05-23 BR BR112018074185-0A patent/BR112018074185A2/pt not_active IP Right Cessation
- 2017-05-23 SG SG11201810366WA patent/SG11201810366WA/en unknown
- 2017-05-23 EP EP17724833.3A patent/EP3464248B1/en active Active
- 2017-05-23 EA EA201892666A patent/EA201892666A1/ru unknown
- 2017-05-23 CA CA3025227A patent/CA3025227A1/en active Pending
- 2017-05-24 UY UY0001037256A patent/UY37256A/es not_active Application Discontinuation
- 2017-05-25 TW TW106117299A patent/TW201742859A/zh unknown
-
2018
- 2018-11-15 IL IL263046A patent/IL263046A/en unknown
- 2018-11-23 CO CONC2018/0012654A patent/CO2018012654A2/es unknown
- 2018-11-23 EC ECSENADI201887725A patent/ECSP18087725A/es unknown
- 2018-11-23 DO DO2018000256A patent/DOP2018000256A/es unknown
- 2018-11-23 SV SV2018005787A patent/SV2018005787A/es unknown
- 2018-11-23 CL CL2018003345A patent/CL2018003345A1/es unknown
- 2018-11-23 NI NI201800124A patent/NI201800124A/es unknown
- 2018-11-23 PH PH12018502472A patent/PH12018502472A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11040035B2 (en) | 2021-06-22 |
| WO2017202816A1 (en) | 2017-11-30 |
| US20200237757A1 (en) | 2020-07-30 |
| CL2018003345A1 (es) | 2019-03-15 |
| EA201892666A1 (ru) | 2019-08-30 |
| TN2018000392A1 (en) | 2020-06-15 |
| CN109863140B (zh) | 2023-02-21 |
| TW201742859A (zh) | 2017-12-16 |
| CO2018012654A2 (es) | 2018-12-14 |
| DOP2018000256A (es) | 2019-02-15 |
| CU20180143A7 (es) | 2019-07-04 |
| KR20190009369A (ko) | 2019-01-28 |
| NI201800124A (es) | 2019-04-29 |
| EP3464248A1 (en) | 2019-04-10 |
| PH12018502472A1 (en) | 2019-09-23 |
| EP3464248B1 (en) | 2021-09-08 |
| CA3025227A1 (en) | 2017-11-30 |
| BR112018074185A2 (pt) | 2019-03-06 |
| IL263046A (en) | 2018-12-31 |
| CN109863140A (zh) | 2019-06-07 |
| SV2018005787A (es) | 2019-02-07 |
| JP6964096B2 (ja) | 2021-11-10 |
| UY37256A (es) | 2018-01-02 |
| JP2019516744A (ja) | 2019-06-20 |
| CR20180556A (es) | 2019-04-23 |
| SG11201810366WA (en) | 2018-12-28 |
| MA45087A (fr) | 2021-05-26 |
| AU2017269870A1 (en) | 2018-12-06 |
| ECSP18087725A (es) | 2018-11-30 |
| PE20190509A1 (es) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502472A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| PH12019501846A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| SA522432734B1 (ar) | مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـثنائي أسيل غليسرول كيناز ألفا من أجل تنشيط المناعة | |
| PH12019501034A1 (en) | New anthelmintic quinoline-3-carboxamide derivatives | |
| PH12019502851A1 (en) | New azaquinoline derivatives | |
| PH12020500257A1 (en) | Quinoline derivatives for treating infections with helminths | |
| PH12018550173A1 (en) | Pyrazolopyrimidine derivatives | |
| PH12022550353A1 (en) | [1,2,4]triazolo[1,5-c]quinazolin-5-amines | |
| PH12020551891A1 (en) | New quinoline derivatives | |
| PH12020500134A1 (en) | Dihydrooxadiazinones | |
| WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
| PH12019502365A1 (en) | New bicyclic pyrazole derivatives | |
| PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
| WO2017198341A8 (en) | MACROCYCLIC INDOLE DERIVATIVES | |
| SA518400501B1 (ar) | مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل) | |
| EA201991835A1 (ru) | 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования | |
| NZ800047A (en) | Benzimidazolone derived inhibitors of bcl6 |